title: [Non-small cell lung cancer: HER2 oncogene status].
abstract: OBJECTIVE
  to study HER2 protein and HER2 gene, their heterogeneity in non-small cell lung cancer.
  
  
  METHODS
  218 intraoperative non-small cell lung samples were examined using tissue matrix methods. HER2 protein was determined by immunohistochemistry (clone 4B5, <<Ventana>> and HER2 gene and CEP1 7 were evaluated by in situ hybridization (SISH, <<Ventana>>).
  
  
  RESULTS
  Positive and indefinite statuses were found in 59 (27%) and 47 (22%) cases, respectively; intratumor heterogeneity was detected in 32 (30%) cases. Amplification of the HER-2 gene was found in 12 (6%) cases; that of the HER2 gene along with an increase in CEPI 7 was observed in 7 (3%) cases; elevated CEP1 7 levels were seen in 19 (9%) cases. Intratumor heterogeneity of HER2 gene amplification was not found; however, one case of adenocarcinoma showed high-level HER2 gene amplification in the gland-like areas and low-level HER2 gene amplification in the solid areas. HER2-positive status and amplification were more common in adenocarcinoma than in squamous cell carcinoma (p<0.001). There was a moderate correlation between HER2 immunohistochemical status and amplification (r=0.38; p<0.001).
  
  
  CONCLUSIONS
  Thus, in non-small cell lung cancer, there is an elevated HER2 protein level and, well less frequently, altered activity in the HER2 gene (amplification) as a cause of enhanced protein synthesis.
authors.affiliation: Kogalym Town Hospital, Kogalym, Tyumen Regшon.
authors.forename: D S
authors.initials: DS
authors.lastname: Kobyakov
authors.affiliation: Laboratory of Molecular Diagnosis, Altai Branch, N.N. Blokhin Russian Cancer Research Center, Barnaul.
authors.forename: A M
authors.initials: AM
authors.lastname: Avdalyan
authors.affiliation: Department of Morbid Anatomy, Altai Medical University, Barnaul.
authors.forename: V V
authors.initials: VV
authors.lastname: Klimachev
authors.affiliation: Laboratory of Molecular Diagnosis, Altai Branch, N.N. Blokhin Russian Cancer Research Center, Barnaul.
authors.forename: A F
authors.initials: AF
authors.lastname: Lazarev
authors.affiliation: Research Institute of Regional Pathology and Pathomorphology, Siberian Branch, Russian Academy of Medical Sciences, Novosibirsk.
authors.forename: E L
authors.initials: EL
authors.lastname: Lushnikova
authors.affiliation: Research Institute of Regional Pathology and Pathomorphology, Siberian Branch, Russian Academy of Medical Sciences, Novosibirsk.
authors.forename: L M
authors.initials: LM
authors.lastname: Nepomnyaschikh
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000453:epidemiology / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D018734:Genes, erbB-2; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D008175:Lung Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D015995:Prevalence; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human